Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

ion are as follows: The IL-3Ralpha-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm CellsAbstract #: 2588Lead Author:  Fanny Angelot-Delettre, PhD, Institut National de la Sante et de la Recherche MedicaleSession: 614. Acute Lymphoblastic Leukemia - Therapy, excluding Transplantation: Poster IIDate/Time: Sunday, December 11, 2011; 6:00 - 8:00pm PTLocation: Hall GH (San Diego Convention Center) Hodgkin's Lymphoma Cell Lines Have Up-Regulated IL-3 Receptor alpha (IL-3Ralpha) Expression and Are Sensitive to SL-401, An IL-3Ralpha-Targeted Drug Abstract #: 3737Lead Author: Catherine Diefenbach, MD, New York University Cancer InstituteSession: 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster IIIDate/Time: Monday, December 12, 2011; 6:00 - 8:00pm PTLocation: Hall GH (San Diego Convention Center) A copy of the above referenced abstracts can be viewed online through the ASH website at www.hematology.org.

About SL-401

SL-401 is a novel clinically active oncology compound that targets the interleukin-3 receptor (IL-3R). IL-3R is overexpressed on cancer stem cells (CSCs) and tumor bulk of multiple hematologic cancers. In a Phase I/II trial of patients with advanced acute myeloid leukemia (AML), SL-401 demonstrated single agent efficacy, including complete responses (CRs) and an overall survival benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. Given these promising results, SL-401 is being advanced into later stage trials in this indication. SL-401 is also being clinically tested in Phase I/II studies of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myeloid leukemia (CML). SL-401 was granted Orphan Drug Designation by the FDA for the treatment of AML.

About Stemline Therapeutics, Inc.Stemline Therapeutics, Inc. is a clinical stage biopharmac
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... (PRWEB) May 05, 2015 Synedgen Inc. ... PhD as Regulatory Affairs Manager. , Dr. Nguyen brings ... important juncture for the company as it moves forward ... products over the next two years. Dr. Nguyen will ... all the regulatory key documents that must be completed ...
(Date:5/4/2015)... , May 4, 2015   St. Jude ... significantly better computer tool for finding genetic alterations ... but were difficult to identify with whole-genome sequencing. ... Nature Methods . The tool ... Number Segmentation by Regression Tree in Next Generation ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Golden ... Kong listed company and a substantial shareholder ... "Agreement") to purchase the Company,s outstanding 7% senior convertible ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... CytoDyn , a New Mexico-based biotechnology company, has ... manufacture its DNA-based, pre-flu vaccine. , ,Located ... the biomanufacturing facility is designed to manufacture clinical-grade biological ... trials. CytoDyn hopes to have clinical trials underway before ...
... David M. Kettner, who has served as in-house counsel for ... post after March 30 to become chief intellectual property counsel ... emphasized biotech patent prosecution and intellectual property licensing, will continue ... for a period of time after March 30. At WARF, ...
... Corp . and Imaxio S.A. (Saint-Beauzire, France) ... to manufacture and sell OverExpress bacterial cells ... will retain the right to license the use of ... the cells to commercial licensees. No license will be ...
Cached Biology Technology:Lucigen Corp. enters global licensing agreement 2
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... A team of scientists from the University of Maryland ... the Gulf of Mexico later this summer to study the ... and fish communities in the northern Gulf. The National Science ... for the expedition, which will be led by Laboratory Director ...
... held June 21-22, 2010, in Baltimore, Md., at ... business, science, education and government leaders to discuss ... glass materials used in advanced armor, semiconductors, turbines, ... filters, nuclear reactors and high-strength "smart" construction materials. ...
... that the Earth has been gradually warming as the result ... to stop it, according to a new survey by researchers ... The survey was conducted by Woods Institute Senior Fellow ... at Stanford, with funding from the National Science Foundation. The ...
Cached Biology News:Large majority of Americans still believe in global warming, Stanford poll finds 2Large majority of Americans still believe in global warming, Stanford poll finds 3
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
... PlusOne Silver Staining Kit, Protein, ... Heukeshoven and Dernick (1), the kit ... gel electrophoresis systems.Silver Staining Kit, Protein ... of proteins in polyacrylamide gels in ...
Cyno macaque plasma and serum - various quantities available...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Biology Products: